Hotline: 1800 102 2007
Hotline: 1800 102 2007
Mar, 07 2017

To streamline business Cipla sells its animal health business to Ascendis for Rs 190 crore

Cipla's animal health division operates mainly in the farm animal segment and its main products include antimicrobials, endectocides, proton pump inhibitors, non-steroidal anti-inflammatory drugs, and supplements.

To streamline business Cipla sells its animal health business to Ascendis for Rs 190 crore

Drug manufacturer Cipla has sold its animal health business in South Africa to Ascendis Health for around Rs 190 crore as part of its strategy to streamline business and focus on core therapies.

Cipla's animal health portfolio, which exists in India and Africa, contributes less than one per cent to the company's consolidated revenue.

The drug maker said it had signed an agreement to divest its 100 per cent stake in two South African entities — Cipla Agrimed and Cipla Vet.

The total consideration of the transaction would be 375 million South African Rand (around Rs 190 crore) with potential revision linked to the performance in financial year 2017 (within the price band of 250 million Rand and 500 million Rand).

Cipla's animal health division operates mainly in the farm animal segment and its main products include antimicrobials, endectocides, proton pump inhibitors, non-steroidal anti-inflammatory drugs, and supplements.

In a statement, Cipla South Africa CEO Paul Miller said that the company will increase its focus and efforts in advancing healthcare for all South Africans and will grow its portfolio of quality and affordable products and therapies.

The sale of the animal health business is in line with the company's strategy to cut down on non-core businesses and focus on key areas, including the respiratory segment.

Its key markets include India, South Africa and the US. Last year, it exited from several markets to reduce costs and complexities and also sold its stake in clinical stage biopharmaceutical company Chase Pharmaceuticals to Allergan.

From Cipla’s folio India, US and South Africa key markets for Cipla. Account for over 70 per cent of revenue Sale of animal health business is in line with the focus being on key therapy areas such as respiratory Cipla is exiting non-core businesses to reduce costs and complexities Animal health business contributes to less than one per cent of Cipla’s consolidated revenue

sharebtn
Comment
user
email
mobile
address
star
Related opportunities
  • Casual Dine Restaurants
    Fromage, as the name suggests, is the Cheesiest place in..
    Locations looking for expansion Haryana
    Establishment year 2017
    Franchising Launch Date 2020
    Investment size Rs. 10lac - 20lac
    Space required -NA-
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Faridabad Haryana
  • Institutional/Facility Cleaning
    “Pharvinex Chemicals and Intermediates” is one of the most trusted..
    Locations looking for expansion Rajasthan
    Establishment year 2018
    Franchising Launch Date 2018
    Investment size Rs. 10000 - 50000
    Space required 300
    Franchise Outlets -NA-
    Franchise Type MultiUnit
    Headquater Kota Rajasthan
  • About Us: TTK Prestige Limited - India’s largest kitchen ware company..
    Locations looking for expansion KARNATAKA
    Establishment year 1957
    Franchising Launch Date 2003
    Investment size Rs. 10lac - 20lac
    Space required 400-1000 sft
    Franchise Outlets 500-1000
    Franchise Type Unit, Multiunit
    Headquater BENGALURU KARNATAKA
  • Electric Vehicles
    Electric rickshaws (also known as Tuk Tuk, e-rickshaw) have been..
    Locations looking for expansion Haryana
    Establishment year 2015
    Franchising Launch Date 2020
    Investment size Rs. 10lac - 20lac
    Space required 1900
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Faridabad Haryana
Daily Updates
Submit your email address to receive the latest updates on news & host of opportunities